Login
Companies $LXEO
$3.23 +$0.00 (0.0%) After hours
Lexeo Therapeutics, Inc. logo

Lexeo Therapeutics, Inc.

lexeotx.com

What Do They Do?

Develops genetic medicine candidates, led by gene therapies for inherited heart diseases, for people with cardiovascular and genetic diseases.

How Are They Changing?

Since the FY2025 annual report
Latest quarter: Q3 FY2026, the three months to Sep 30, 2026
Net income
▼ −89% (Loss)
vs −$20.3M in Q3 FY2025
  • Sep 29, 2026 Lexeo completed its acquisition of Mantle Therapeutics Mantle shareholders received an upfront purchase price in cash and Lexeo shares, with additional payments tied to development and regulatory milestones.

Who Do They Compete With?

Competes with Solid Biosciences, Voyager Therapeutics, Neurocrine Biosciences, Larimar Therapeutics, PTC Therapeutics, Reata Pharmaceuticals, Biogen, Rocket Pharmaceuticals, and Tenaya Therapeutics

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support